Ipilimumab
Astrocytoma, IDH-Mutant, Grade 4
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Astrocytoma, IDH-Mutant, Grade 4 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safusidenib Nuvation Bio Inc. | Phase 3 | B |
Nivolumab Andrew P. Groves | Phase 2 | B |
gi-102 Mayo Clinic | Phase 2 | CCC |
Pembrolizumab Mayo Clinic | Phase 2 | CCC |
gsk1120212 St. Jude Children's Research Hospital | Phase 1 | CC |
View all 15 →
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →